{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T10:17:34Z","timestamp":1756635454562},"reference-count":0,"publisher":"Farmarus Print Media","issue":"1-1 part: 16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>\u041f\u0435\u0440\u0432\u044b\u043c \u0442\u0430\u0440\u0433\u0435\u0442\u043d\u044b\u043c (\u0446\u0435\u043b\u0435\u0432\u044b\u043c) \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u043e\u043c, \u043a\u043e\u0442\u043e\u0440\u044b\u0439 \u043f\u0440\u0438\u043c\u0435\u043d\u044f\u0435\u0442\u0441\u044f \u0443 \u043f\u0430\u0446\u0438\u0435\u043d\u0442\u043e\u0432 \u0441 \u043d\u0435\u043a\u043e\u043d\u0442\u0440\u043e\u043b\u0438\u0440\u0443\u0435\u043c\u043e\u0439 \u0441\u0440\u0435\u0434\u043d\u0435\u0442\u044f\u0436\u0435\u043b\u043e\u0439 \u0438 \u0442\u044f\u0436\u0435\u043b\u043e\u0439 \u0431\u0440\u043e\u043d\u0445\u0438\u0430\u043b\u044c\u043d\u043e\u0439 \u0430\u0441\u0442\u043c\u043e\u0439 (\u0411\u0410), \u0441\u0442\u0430\u043b \u0430\u043d\u0442\u0438-IgE \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442 \u043e\u043c\u0430\u043b\u0438\u0437\u0443\u043c\u0430\u0431 (\u041a\u0441\u043e\u043b\u0430\u0440). \u042d\u0442\u043e\u0442 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442 \u043d\u0430\u0437\u043d\u0430\u0447\u0430\u0435\u0442\u0441\u044f \u043f\u0430\u0446\u0438\u0435\u043d\u0442\u0430\u043c \u0441\u043e \u0441\u0440\u0435\u0434\u043d\u0435\u0442\u044f\u0436\u0435\u043b\u043e\u0439 \u0438 \u0442\u044f\u0436\u0435\u043b\u043e\u0439 \u0430\u0442\u043e\u043f\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0411\u0410, \u043a\u043e\u0442\u043e\u0440\u0430\u044f \u043d\u0435 \u043a\u043e\u043d\u0442\u0440\u043e\u043b\u0438\u0440\u0443\u0435\u0442\u0441\u044f \u0431\u0430\u0437\u0438\u0441\u043d\u043e\u0439 \u0442\u0435\u0440\u0430\u043f\u0438\u0435\u0439, \u0441\u043e\u043e\u0442\u0432\u0435\u0442\u0441\u0442\u0432\u0443\u044e\u0449\u0435\u0439 \u0441\u0442\u0443\u043f\u0435\u043d\u0438 4 (\u0443\u0440\u043e\u0432\u0435\u043d\u044c \u0434\u043e\u043a\u0430\u0437\u0430\u0442\u0435\u043b\u044c\u043d\u043e\u0441\u0442\u0438 \u0410). \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u044f \u0443\u0431\u0435\u0434\u0438\u0442\u0435\u043b\u044c\u043d\u043e \u043f\u0440\u043e\u0434\u0435\u043c\u043e\u043d\u0441\u0442\u0440\u0438\u0440\u043e\u0432\u0430\u043b\u0438, \u0447\u0442\u043e \u0443 \u043f\u0430\u0446\u0438\u0435\u043d\u0442\u043e\u0432 \u0441 \u0442\u044f\u0436\u0435\u043b\u043e\u0439 \u0430\u0441\u0442\u043c\u043e\u0439, \u0442\u0440\u0435\u0431\u0443\u044e\u0449\u0438\u0445 \u0442\u0435\u0440\u0430\u043f\u0438\u0438 \u0432\u044b\u0441\u043e\u043a\u0438\u043c\u0438 \u0434\u043e\u0437\u0430\u043c\u0438 \u0438\u043d\u0433\u0430\u043b\u044f\u0446\u0438\u043e\u043d\u043d\u044b\u0445 \u043a\u043e\u0440\u0442\u0438\u043a\u043e\u0441\u0442\u0435\u0440\u043e\u0438\u0434\u043e\u0432 \u0438\u043b\u0438 \u043f\u0435\u0440\u043e\u0440\u0430\u043b\u044c\u043d\u044b\u043c\u0438 \u0433\u043b\u044e\u043a\u043e\u043a\u043e\u0440\u0442\u0438\u043a\u043e\u0441\u0442\u0435\u0440\u043e\u0438\u0434\u0430\u043c\u0438, \u043b\u0435\u0447\u0435\u043d\u0438\u0435 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u043e\u043c \u041a\u0441\u043e\u043b\u0430\u0440 \u0441\u043d\u0438\u0436\u0430\u0435\u0442 \u0447\u0430\u0441\u0442\u043e\u0442\u0443 \u043e\u0431\u043e\u0441\u0442\u0440\u0435\u043d\u0438\u0439 \u0411\u0410, \u0443\u043c\u0435\u043d\u044c\u0448\u0430\u0435\u0442 \u0441\u0442\u0435\u043f\u0435\u043d\u044c \u0442\u044f\u0436\u0435\u0441\u0442\u0438 \u0430\u0441\u0442\u043c\u044b \u0438 \u043f\u043e\u0437\u0432\u043e\u043b\u044f\u0435\u0442 \u043f\u0440\u0438 \u0441\u0442\u0435\u0440\u043e\u0438\u0434\u043e\u0437\u0430\u0432\u0438\u0441\u0438\u043c\u043e\u0439 \u0411\u0410 \u043e\u0442\u043c\u0435\u043d\u044f\u0442\u044c \u0438\u043b\u0438 \u0437\u043d\u0430\u0447\u0438\u0442\u0435\u043b\u044c\u043d\u043e \u0441\u043d\u0438\u0436\u0430\u0442\u044c \u0434\u043e\u0437\u044b \u0441\u0438\u0441\u0442\u0435\u043c\u043d\u044b\u0445 \u043a\u043e\u0440\u0442\u0438\u043a\u043e\u0441\u0442\u0435\u0440\u043e\u0438\u0434\u043e\u0432. \u041a\u0440\u043e\u043c\u0435 \u0442\u043e\u0433\u043e, \u0434\u043e\u043a\u0430\u0437\u0430\u043d \u043f\u0440\u043e\u0442\u0438\u0432\u043e\u0432\u043e\u0441\u043f\u0430\u043b\u0438\u0442\u0435\u043b\u044c\u043d\u044b\u0439 \u044d\u0444\u0444\u0435\u043a\u0442 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0430. \u0418\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u044f \u043f\u043e\u0441\u043b\u0435\u0434\u043d\u0438\u0445 \u043b\u0435\u0442 \u043f\u0440\u0438\u0432\u043e\u0434\u044f\u0442 \u0432\u0441\u0435 \u0431\u043e\u043b\u044c\u0448\u0435 \u0434\u0430\u043d\u043d\u044b\u0445 \u043e \u043f\u043e\u043b\u043e\u0436\u0438\u0442\u0435\u043b\u044c\u043d\u043e\u043c \u0432\u043b\u0438\u044f\u043d\u0438\u0438 \u043e\u043c\u0430\u043b\u0438\u0437\u0443\u043c\u0430\u0431\u0430 \u043d\u0430 \u0440\u0435\u043c\u043e\u0434\u0435\u043b\u0438\u0440\u043e\u0432\u0430\u043d\u0438\u0435 \u0434\u044b\u0445\u0430\u0442\u0435\u043b\u044c\u043d\u044b\u0445 \u043f\u0443\u0442\u0435\u0439.<\/jats:p><jats:p>The first targeted drug that is used for patients with uncontrolled moderate and severe atopic asthma (BA) was anti-IgE drug omalizumab (Xolar). This drug is prescribed to patients with moderate to severe atopic BA, which is not controlled by baseline therapy corresponding to stage 4 (level of evidence A). Clinical studies have convincingly demonstrated that in patients with severe asthma requiring treatment with high doses of inhaled corticosteroids or oral glucocorticosteroids, treatment with Xolar reduces the frequency of exacerbations of BA, reduces the severity of asthma and allows for steroid-dependent BA to cancel or significantly reduce the dose of systemic corticosteroids. In addition, the anti-inflammatory effect of the drug has been proven. Studies in recent years provide more and more data on the positive impact of omalizumab on the remodeling of the respiratory tract.<\/jats:p>","DOI":"10.36691\/raj.2019.1-1.53227","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T22:13:55Z","timestamp":1580249635000},"source":"Crossref","is-referenced-by-count":2,"title":["\u0410\u041d\u0422\u0418-IGE \u0422\u0415\u0420\u0410\u041f\u0418\u042f \u0422\u042f\u0416\u0415\u041b\u041e\u0419 \u0410\u0422\u041e\u041f\u0418\u0427\u0415\u0421\u041a\u041e\u0419 \u0411\u0420\u041e\u041d\u0425\u0418\u0410\u041b\u042c\u041d\u041e\u0419 \u0410\u0421\u0422\u041c\u042b"],"prefix":"10.36691","author":[{"given":"N.P.","family":"Knyazheskaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.S.","family":"Belevskiy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.V.","family":"Safoshkina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22679","published-online":{"date-parts":[[2019,3,18]]},"container-title":["Rossiiskii Allergologicheskii ZHurnal"],"original-title":["\u0410\u041d\u0422\u0418-IGE \u0422\u0415\u0420\u0410\u041f\u0418\u042f \u0422\u042f\u0416\u0415\u041b\u041e\u0419 \u0410\u0422\u041e\u041f\u0418\u0427\u0415\u0421\u041a\u041e\u0419 \u0411\u0420\u041e\u041d\u0425\u0418\u0410\u041b\u042c\u041d\u041e\u0419 \u0410\u0421\u0422\u041c\u042b"],"deposited":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T22:14:04Z","timestamp":1580249644000},"score":1,"resource":{"primary":{"URL":"https:\/\/elibrary.ru\/item.asp?id=37256442"}},"subtitle":["Anti-IgE therapy for severe atopic asthma"],"short-title":[],"issued":{"date-parts":[[2019,3,18]]},"references-count":0,"journal-issue":{"issue":"1-1 part: 16","published-online":{"date-parts":[[2019,3,18]]}},"URL":"https:\/\/doi.org\/10.36691\/raj.2019.1-1.53227","relation":{},"ISSN":["2686-682X"],"issn-type":[{"value":"2686-682X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,18]]}}}